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ABSTRACT
Objectives To determine whether patients with 
early rheumatoid arthritis (ERA) have cardiovascular 
disease (CVD) that is modifiable with disease- modifying 
antirheumatic drug (DMARD) therapy, comparing first- line 
etanercept (ETN) + methotrexate (MTX) with MTX strategy.
Methods Patients from a phase IV ERA trial randomised 
to ETN+MTX or MTX strategy±month 6 escalation to 
ETN+MTX, and with no CVD and maximum one traditional 
risk factor underwent cardiovascular magnetic resonance 
(CMR) at baseline, years 1 and 2. Thirty matched controls 
underwent CMR. Primary outcome measure was aortic 
distensibility (AD) between controls and ERA, and baseline 
to year 1 AD change in ERA. Secondary analyses between 
and within ERA groups performed. Additional outcome 
measures included left ventricular (LV) mass and myocardial 
extracellular volume (ECV).
Results Eighty- one patients recruited. In ERA versus 
controls, respectively, baseline (geometric mean, 95% CI) 
AD was significantly lower (3.0×10−3 mm Hg−1 (2.7–3.3) 
vs 4.4×10−3 mm Hg−1 (3.7–5.2), p<0.001); LV mass 
significantly lower (78.2 g (74.0–82.7), n=81 vs 92.9 g 
(84.8–101.7), n=30, p<0.01); and ECV increased (27.1% 
(26.4–27.9), n=78 vs 24.9% (23.8–26.1), n=30, p<0.01). 
Across all patients, AD improved significantly from baseline 
to year 1 (3.0×10−3 mm Hg−1 (2.7–3.4) to 3.6×10–3 mm 
Hg−1 (3.1–4.1), respectively, p<0.01), maintained at year 
2. The improvement in AD did not differ between the two 
treatment arms and disease activity state (Disease Activity 
Score with 28 joint count)- erythrocyte sedimentation rate- 
defined responders versus non- responders.
Conclusion We report the first evidence of vascular and 
myocardial abnormalities in an ERA randomised controlled 
trial cohort and show improvement with DMARD therapy. 
The type of DMARD (first- line tumour necrosis factor- 
inhibitors or MTX) and clinical response to therapy did not 
affect CVD markers.
Trial registration number ISRCTN: ISRCTN89222125; 
ClinicalTrials. gov: NCT01295151.
INTRODUCTION
Rheumatoid arthritis (RA) is associated with up to 
threefold increased mortality compared with the 
general population. This is largely due to increased 
frequency of premature cardiovascular disease 
(CVD), notably atherosclerosis and heart failure.1 2 
This excess risk is as high as that of patients with 
major CVD risk factors such as type 2 diabetes 
mellitus3 and is considered independent of and 
incremental to traditional cardiovascular (CV) risk 
factors.4
In addition to traditional risk factors, notably, 
hypertension, smoking and high cholesterol,5 the 
heightened CV risk in RA is thought to be mediated 
by inflammation.4 In the pathogenesis of atheroscle-
rosis, identification of key immune mediators and 
pathways6 has informed recent proof- of- concept 
randomised controlled trials (RCT).7 Such insights 
support the concept of shared immune mechanisms 
Key messages
What is already known about this subject?
 ► Epidemiological studies have shown reduction 
in cardiovascular (CV) events coinciding with 
contemporary management of rheumatoid 
arthritis (RA) and clinical imaging studies have 
illustrated abnormal CV measures, mainly in 
established RA, with varying association to poor 
prognosis factors of RA.
What does this study add?
 ► This first study of an early RA, treatment- 
naïve randomised controlled trial cohort with 
no known CV history and maximum of one 
traditional risk factor (excluding diabetes) 
reveals abnormal vascular stiffness (which 
has been shown to predict major CV events 
independently of traditional clinical risk 
scoring models in patients without known 
cardiovascular disease (CVD)) and evidence 
of diffuse myocardial fibrosis and reduced left 
ventricular mass.
 ► First- line etanercept with methotrexate, or initial 
methotrexate- treat- to- target strategy improved 
vascular stiffness. However, RA treatment 
response and cumulative disease activity do not 
appear to add to this improvement in vascular 
stiffness.
 o
n
 August 29, 2020 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217653 on 28 August 2020. Downloaded from
 
2 Plein S, et al. Ann Rheum Dis 2020;0:1–9. doi:10.1136/annrheumdis-2020-217653
Rheumatoid arthritis
and raise the possibility that RA immune- modulating therapies 
may also influence CVD pathogenesis.
The modest overall CVD event rate in RA8 has necessitated 
studies employing imaging- based surrogate markers of CVD. 
These have illustrated improvement in CVD with RA disease- 
modifying antirheumatic drug (DMARD) therapy, including 
biological DMARDs (bDMARDs) such as tumour necrosis factor 
inhibitors (TNFi) bDMARD9 but translation to clinical practice has 
been limited. Of the various modalities, cardiovascular magnetic 
resonance (CMR) offers the most sensitive tool for the assessment 
of CVD, with the advantage of providing multiparametric anatom-
ical, functional, perfusion and tissue characteristic assessment.10
This study was originally coined the Coronary Artery Disease 
in Early RA study but designed as a wider CArdiovascular 
Disease Evaluation in RA,11 a first bolt- on study to a parent RCT 
in an early RA (ERA) inception cohort.12 The objectives are to 
evaluate whether patients with treatment- naive ERA demon-
strate myocardial and vascular changes on CMR compared with 
controls; whether abnormalities are modifiable over a 1- year 
period with DMARD strategies and maintained over 2 years; 
and whether the type of intervention (standard of care metho-
trexate (MTX)- treat to target (MTX- TT)13) or TNFi and MTX) 
affects extent of change in CV abnormality.
METHODS
All participants provided written informed consent. Detailed 
trial protocols for both the parent RCT (called ‘VEDERA’)12 and 
this study11 have been published.
Participants
Patients were recruited between February 2012 and November 
2015. Consecutive patients diagnosed with new- onset RA 
according to American College of Rheumatology/European 
League Against Rheumatism 2010 criteria14 were invited to enrol 
into the VEDERA RCT and this substudy. The principal eligi-
bility criteria included: no previous DMARD exposure, symptom 
duration ≤12 months, at least moderate disease activity (Disease 
Activity Score with 28 joint count (DAS28- ESR) ≥ 3.2) and one 
Figure 1 Cardiac MRI protocol. LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular.
Key messages
How might this impact on clinical practice or future 
developments?
 ► These data imply benefits of therapy beyond suppression of 
systemic inflammation, likely suggesting cardiometabolic 
changes and targeted effects on key immune mediators of 
CVD.
 ► This study builds on the concept of targeted therapeutics in 
atherosclerosis, whereby immune modulating treatment may 
be personalised in stratified patients with RA to not only 
improve joint specific outcome, but also CVD.
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poor prognostic factor (positive rheumatoid factor±anticitrul-
linated protein antibody±abnormal ultrasound power Doppler 
in any joint) and a maximum of one traditional CVD risk factor. 
Diabetes mellitus was excluded in all patients.
As part of the parent RCT,12 all patients were randomised on 
a 1:1 basis either to: first- line TNFi, etanercept (ETN) + MTX 
(15 mg weekly, optimised to 25 mg weekly by week 8); or first- 
line MTX- TT (MTX monotherapy 15 mg weekly increased to 
25 mg weekly at 2 weeks with further protocolised csDMARD 
escalation if indicated). At week 24, MTX- TT patients escalated 
to ETN + MTX if they failed to achieve DAS28- ESR remission 
(DAS28- ESR≥2.6). At year 1, all patients on ETN stopped the 
TNFi and standard of care was maintained, with further 1- year 
observation period. Full details are included in the online supple-
mentary file.
Controls
Thirty healthy volunteers (controls) with no history or risk 
factors for CVD were matched to the first 30 study patients by 
age and sex (see online supplementary file for details) and under-
went a single CMR scan.
CMR imaging
CMR scans were conducted at baseline (prior to the commence-
ment of randomised treatment), 1 and 2 years after enrolment. 
All scans were performed on the same 3.0T system (Philips 
Achieva, Best, The Netherlands). The CMR protocol is illustrated 
in figure 1, summarised in the online supplementary file and has 
previously been described.11 15 CMR analysis was performed 
using CVI V.42 software (Circle Cardiovascular Imaging Calgary, 
Canada) by two assessors (GF, BE) both with 2 years of experi-
ence and supervised by a senior CMR expert (SP). The following 
measurements were made: aortic distensibility (AD), left ventric-
ular (LV) volume and mass, native T1 and myocardial extracel-
lular volume (ECV). Late gadolinium enhancement (LGE) and 
stress and rest perfusion images were visually assessed by the 
presence and distribution of hyperenhancement and inducible 
regional perfusion defects, respectively.
Blinding
The CV radiographer and investigators who performed and 
analysed the scans, respectively, were blinded to treatment arm, 
specific treatment allocation and the RA clinical trial data over 
the entire study duration. Similarly, as previously reported for 
the parent RCT,12 RA clinical assessments were undertaken by 
blinded joint count assessors to inform the RA trial outcomes.
Statistical analysis
Outcome measures
The primary outcome measure was AD, as a measure of aortic 
stiffness. AD has been shown to predict CV outcomes in several 
conditions, including hypertension16 and asymptomatic patients 
with diabetes,17 and is highly reproducible.18 Secondary outcome 
measures included LV ejection fraction, LV mass, LV longitudinal 
strain (LVLS), peak left ventricular twist (PLVTw) and perfusion. 
Myocardial T1 and ECV were exploratory outcome measures.
Sample size calculation
Based on a previous study showing improved AD in patients 
with RA in response to interleukin (IL)-1 directed therapy,19 we 
proposed 2.46 as an effect size (representing 75% of the differ-
ence between treated and non- treated patients with RA previ-
ously reported19). Assuming an SD of 2.5, 5% significance level 
in a two- tailed independent samples t- test at 90% power, 25 
patients would be required per group, ETN- MTX and MTX- TT 
(adjusting for 10% drop- out).
Analysis methods
For comparisons between study patient and control groups, two 
different analyses were conducted on the primary, secondary and 
exploratory outcomes. Directly matched patients and controls 
were compared using paired Student’s t- tests. To maximise the 
data available and reflect the resulting approximate matching, 
linear regression analyses are also presented for all outcomes 
at baseline including the 30 controls and all patients with ERA. 
Each analysis is presented unadjusted (with a single independent 
variable case/control) and adjusted (with independent variables 
case/control, age, sex, systolic blood pressure and pack years 
smoked).
For analysis of outcomes at 1- year and 2- year follow- up, anal-
ysis of covariance was adopted. The outcome at follow- up is 
linearly regressed on a grouping variable (defined below), first as 
an unadjusted analysis (exploring differences by subgroup in the 
outcome at 1 or 2 years), second adjusted for baseline value of 
the outcome and third, additionally adjusted for baseline value, 
age, sex, systolic blood pressure and, where appropriate, base-
line DAS28- ESR.
The primary outcome, AD, was analysed using an intention- 
to- treat approach with multiple imputation (see online supple-
mentary file) to address missing data. Treatment response was 
defined as achievement of DAS28- ESR remission (<2.6; the 
primary endpoint of the VEDERA RCT). Patients with missing 
DAS28 at week 48 due to reasons other than withdrawal for 
lack of efficacy (LOE) were first assumed to be responders in 
the analysis. Data were then reimputed and reanalysed assuming 
they were non- responders (no difference was identified).
Interval change in AD from baseline to year 1 analysis was 
assessed in a stepwise fashion as follows: change in AD from 
baseline to year 1 was evaluated in the whole RA group. AD 
at 1 year was compared between the following groups to 
understand the effect of RA DAS28 control and/or any inde-
pendent drug effect: ETN- MTX (all patients) versus MTX- TT 
(all patients); combined ETN- MTX and MTX- TT (responders) 
versus combined ETN- MTX and MTX- TT (non- responders) 
adjusting for baseline DAS28ESR; ETN- MTX (responders) and 
ETN- MTX (non- responders) adjusting for baseline DAS28ESR; 
ETN- MTX (responders) and MTX- TT responders (no ETN 
exposure) adjusting for baseline DAS28ESR. Statistical analysis 
was performed using and R V.2.14.1 (The R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
Patient recruitment and numbers
Eighty- two patients were enrolled and underwent baseline 
CMR. In one patient, no AD could be acquired (but they had all 
other assessments). Of the n=81 with complete baseline CMR, 
71 underwent a 1- year scan and 57 a 2- year scan (figure 2).
Withdrawals
Eleven patients did not have follow- up CMR at 1 year. One 
was withdrawn due to treatment non- compliance, one due to 
non- response and three due to treatment- related serious adverse 
events (AE). Three patients declined repeat CMR, two had claus-
trophobia and one patient moved away. At year 2, a further 14 
patients were withdrawn, 1 due to treatment non- compliance, 
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 Figure  1: CONSORT diagram 
VEDERA recruited patients (n=120) 
assessed for CADERA eligibility 
Excluded (not meeting target population 
+/- declined; n=39) 
Full analysis set (n=40) 
 
Number without year 1 CMR (n=5) 
 Declined (n=1) 
 Claustrophobia (n=1) 
 Withdrawn from VEDERA (n=3; x1 SAE, x1 non-
response, x1 non-compliance) 
Number without year 1 CMR (n=6) 
 Declined (n=2) 
 Claustrophobia (n=1) 
 Withdrawn from VEDERA (n=2; SAE) 
 Other (n=1) 
 
Full analysis set (n=41) 
 
Analysis 
Primary endpoint: year 1 
Recruited to CADERA n=81  
Enrolment 
Number without year 2 CMR (n=7):  
 Declined (n=3) 
 Withdrawn from VEDERA (n=1 AE) 
 Unable to contact (n=3) 
 
Number without year 2 CMR (n=7):  
 Declined (n=2) 
 Withdrawn from VEDERA (n=3; x2 pregnancy-
related, x1 non-compliance) 
 Unable to contact (n=2) 
 
Final visit: year 2 
TA1: Allocated to early etanercept (n=40) 
 Received allocated intervention (n=40) 
TA2: Allocated to MTX-TT +/- delayed etanercept (n=41) 
 Received allocated intervention (n=41) 
Allocation 
Figure 2 Consolidated Standards of Reporting Trials diagram. Etanercept- methotrexate (ETN- MTX) = treatment arm 1; MTX- treat to target (TT) = 
treatment arm 2. TA1 year 1: n=20 responders; n=17 non- responders; 3 unknown. TA2 year 1: n=15 responders; n=21 non- responders; 5 unknown. 
AE, adverse event; CADREA, Coronary Artery Disease in Early RA; CMR, cardiovascular magnetic resonance; SAE, serious adverse event.
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1 due to a treatment- related AE and 2 pregnancy related. Five 
patients declined repeat CMR and five could not be contacted.
Baseline demographic data
Demographic data for the controls, ERA cohort and the two 
ERA treatment groups are presented in table 1 (and matched 
control and ERA in online supplementary table S1). The baseline 
characteristics were balanced across the two treatment groups 
with the exception of median pack years of smoking. Patients 
and controls were matched for age and sex. Online supple-
mentary table S2 details the key demographic data relevant for 
the primary outcome, split by those with complete data for all 
outcomes and those that had at least one missing outcome. No 
notable differences were observed.
Primary objectives
Patients versus controls
The primary outcome measure AD was 50% lower in ERA 
compared with controls (geometric mean 3.0×10−3 mm Hg−1, 
n=81 vs 4.4 × 10−3 mm Hg−1, n=30, respectively; ratio 
control:ERA (95% CI) 1.5 (1.2 to 1.8), p<0.01), table 2. This 
difference remained statistically significant when adjusted for 
age, sex, systolic blood pressure and pack years smoked.
LV mass was 20% lower in ERA than controls (p<0.01). ECV 
was 10% higher in ERA versus controls (p<0.01). These differ-
ences remained statistically significant when adjusted for age, 
sex, systolic blood pressure and pack years smoked. No signif-
icant differences were seen between ERA versus controls in the 
other secondary outcome measures (table 2).
Matched pairs analyses corroborated the substantive and 
statistically significant differences between the control and ERA 
groups for AD and ECV; with consistent magnitude and direc-
tion in difference for LV mass (online supplementary table S3).
Baseline to 1-year change
AD improved by 20% from baseline to year 1 across the whole 
ERA cohort (geometric mean 3.0×10−3 mm Hg−1 vs 3.6×10−3 
mm Hg−1, respectively; year 1:baseline ratio (95% CI) 1.2 (1.1 
to 1.3), (p<0.01)), table 3. Seven patients were hypertensive at 
baseline and all on medication. None had a change/escalation in 
antihypertensive therapy through the course of the study aside 
from one patient who had to stop due to an AE.
LV mass geometric mean (95% CI) showed a modest, signif-
icant increase from baseline to 1 year (78.2 g/m2 (73.7 to 83.0) 
to 81.4 g/m2 (76.3 to 86.9); year 1:baseline ratio (95% CI) 1.0 
(1.0 to 1.1), (p=0.01)). There were no significant changes in the 
other secondary outcome measures between baseline and 1- year 
follow- up (table 3).
Secondary objectives
Between the two treatment groups, there was no statistically 
significant difference in the change of AD from baseline to 
year 1 (table 4) or for the secondary outcome measures, LV 
mass and ECV (online supplementary tables S4 and S5, respec-
tively). There were no differences between all responders and 
non- responders, and between first- line ETN +MTX responders 
and non- responders (all adjusted for baseline AD, age and sex; 
table 4). To clarify this apparent absence of effect of disease 
Table 1 Summary of baseline demographic, disease activity and 
comorbidity data for controls and patients
Variable Controls n=30
All patients 
with ERA 
n=81
ETN- MTX 
n=40
MTX- TT 
n=41
Demographics*
  Female % (n/N) 63 (19/30) 69 (55/81) 60 (24/40) 76 (31/41)
  Age, years median (IQR) 54 (23) 51 (21) 48.5 (13.5) 54 (23)
  BMI, median (IQR) 27.0 (7.1) 24.9 (5.4) 25.6 (5.5) 24.6 (5.2)
RA profile, % (n/N)       
  CCP positive N/A 84 (64/76) 82 (31/38) 87 (33/38)
  RF positive N/A 75 (57/76) 68 (26/38) 82 (31/38)
RA disease activity profile, median (IQR) n=77 n=39 n=38
  Baseline DAS28 score N/A 5.3 (1.4) 5.5 (1.6) 5.3 (1.4)
  ESR N/A 30 (30) 31 (33.5) 30 (28.3)
  CRP N/A 8 (23) 8 (27) 8 (17.8)
Traditional CV risk factors, % (n/N; unless otherwise stated)
  Hypertension N/A 7 (6/81) 3 (1/40) 12 (5/41)
  Hypercholesterolaemia N/A 2 (2/81) 0 (0/40) 5 (2/41)
  Diabetes 0 (0/30) 0 (0/81) 0 (0/40) 0 (0/41)
  Family history IHD N/A 5 (4/81) 5 (2/40) 5 (2/41)
  Systolic blood pressure, 
mm Hg median (IQR)
120.5 (13.5) 121 (26) 122 (24.5) 120 (23)
  Pack years smoking, 
years median (IQR)
0 (0.4) 0.1 (10) 0 (5.3) 3 (17.5)
Smoking status n=30 n=76 n=38 n=38
  Current 13 (4/30) 22 (17) 16 (6) 29 (11)
  Former 17 (5/30) 33 (25) 29 (11) 37 (14)
  Never 70 (21/30) 45 (34) 55 (21) 34 (13)
*Denominator that is less than n=81 indicates missing data (not retrieved as original imputation 
model included gender).
BMI, body mass index; CCP, cyclic- citrullinated peptide; CRP, C- reactive protein; DAS28, Disease Activity 
Score-28; ERA, early rheumatoid arthritis; ESR, erythrocyte sedimentation rate; ETN, etanercept; IHD, 
ischaemic heart disease; MTX, methotrexate; NA, not applicable; RF, rheumatoid factor; TA1, immediate 
ETN and MTX treatment; TA2, first- line MTX±additional csDMARD.
Table 2 Unadjusted and adjusted cardiovascular magnetic resonance variables in controls versus early rheumatoid arthritis RA at baseline 
(unadjusted, or adjusted for age, sex, systolic blood pressure and pack years smoked)
Outcome n
Control
Unadjusted geometric 
mean (95% CI)
Cases
Unadjusted geometric 
mean (95% CI)
Control/case,
unadjusted geometric 
mean ratio (95% CI) P value
Control/case,
adjusted geometric 
mean ratio (95% CI) P value
AD (10−3 mm Hg−1) 111 4.4 (3.7 to 5.2) 3.00 (2.7 to 3.3) 1.5 (1.2 to 1.8) <0.01 1.5 (1.3 to 1.7) <0.01
LVEF (%) 111 61.6 (59.7 to 63.7) 60.3 (59.2 to 61.5) 1.0 (1.0 to 1.1) 0.27 1.0 (1.0 to 1.1) 0.38
LVLS (cm/s) 106 1.1 (1.1 to 1.2) 1.1 (1.1 to 1.2) 1.0 (1.0 to 1.1) 0.76 1.0 (0.9 to 1.1) 0.95
PLVTw (°) 106 15.3 (13.9 to 16.9) 15.1 (14.1 to 16.0) 1.0 (0.9 to 1.2) 0.71 1.0 (0.9 to 1.2) 0.69
LV mass (g) 111 92.9 (84.8 to 101.7) 78.2 (74.0 to 82.6) 1.2 (1.1 to 1.3) <0.01 1.2 (1.1 to 1.3) 0.03
Native T1 (ms) 108 1201.8 (1187.2 to 1216.5) 1183.1 (1174.0 to 1192.2) 1.0 (1.0 to 1.0) 0.03 1.0 (1.0 to 1.0) 0.06
ECV (%) 108 24.9 (23.8 to 26.1) 27.2 (26.4 to 27.9) 0.9 (0.9 to 1.0) <0.01 0.9 (0.9 to 1.0) <0.01
AD, aortic distensibility; ECV, myocardial extracellular volume; LVEF, left ventricular ejection fraction; LVLS, left ventricular longitudinal strain; LV mass, left ventricular mass; 
PLVTw, peak left ventricular twist.
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activity represented by response status, correlation analyses 
between AUC disease activity and AD at year 1 in the combined 
ERA group (online supplementary table S6), and between each 
treatment arm (online supplementary table S7) also did not 
identify an association. Comparison of first- line ETN +MTX 
responders with first- line MTX- TT responders (who there-
fore did not require ETN) indicated an unadjusted difference 
in geometric mean AD of 30% (0.7 (0.4 to 1.2)), 20% when 
adjusted for baseline AD (0.8 (0.5 to 1.2)), and 10% when 
adjusted for possible confounders (0.9 (0.60 to 1.18)), not statis-
tically significant (table 4).
2-year outcomes
The geometric mean for AD improved by 10% from baseline to 
year 2 (3.0 × 10−3 mm Hg−1 vs 3.6×10−3 mm Hg−1, respec-
tively; year 2:baseline ratio (95% CI) 1.1 (1.0 to 1.4), p=0.05; 
table 5). As in year 1 analysis, there were no differences between 
responders and non- responders (table 5). The increase in LV 
mass remained significant from baseline to year 2 follow- up 
(78.2 (73.7 to 82.9) 85.5 (79.0 to 92.6); ratio (95% CI) year 
2:baseline 1.1 (1.0 to 1.2), p=0.02), online supplementary table 
S8. Of the other secondary outcome measures, PLVTw showed 
a 10% difference from baseline to 2- year follow- up; ratio year 
2:baseline 1.1 (1.0, 1.2), (p=0.02), online supplementary table 
S8. There were no differences between the treatment arms. 
No other parameters showed statistically significant changes at 
2- year follow- up (online supplementary table S8).
Ten patients with RA had abnormal findings on LGE imaging 
and/or follow- up CMR. In eight patients, inferior RV insertion 
point enhancement was seen (generally considered a non- specific 
finding) and in two patients there was septal enhancement. All 
patients had normal stress/rest perfusion with no regional induc-
ible perfusion defects.
DISCUSSION
We report on the first RCT- based study to assess the effect of 
contemporary RA treatment strategies on preclinical CVD in 
patients with treatment- naïve ERA and no history of CVD. 
At time of diagnosis, compared with controls, patients with 
ERA show reduced vascular distensibility (AD, a surrogate for 
increased risk of CVD), evidence of diffuse myocardial fibrosis 
(increased ECV) and reduced LV mass. Introduction of either of 
the tested RA DMARD strategies improved AD at 1- year and 
2- year follow- up, and first- line ETN+MTX was not superior 
to initial MTX- TT. Treatment response and cumulative disease 
activity do not appear to add to this improvement in AD.
Previous observational studies in established RA have shown 
reduced AD19 20 and abnormal LV remodelling and function21 22 
with improvement following therapy.9 23 Aside from one small 
study,24 none have reported on myocardial and vascular function 
Table 3 Summary of baseline to year 1 outcomes for the whole early rheumatoid arthritis group
Outcome
Geometric mean (95% CI)
Baseline
Geometric mean (95% CI)
1 year Ratio (95% CI), P value
AD (10−3 mm Hg−1) 3.0 (2.7 to 3.4) 3.6 (3.1 to 4.1) 1.2 (1.1 to 1.3), <0.01
LVEF (%) 60.3 (59.1 to 61.6) 59.9 (58.5 to 61.5) 1.0 (1.0 to 1.0), 0.54
LVLS (cm/s) 1.1 (1.1 to 1.2) 1.1 (1.1 to 1.2) 1.0 (1.0 to 1.1), 0.84
PLVTw (°) 14.9 (13.9 to 15.8) 14.6 (13.7 to 15.7) 1.0 (0.9 to 1.1), 0.69
LV mass (g) 78.2 (73.7 to 82.9) 81.4 (76.3 to 86.9) 1.0 (1.0 to 1.1), 0.01
Native T1 (ms) 1183.92 (1174.44 to 1193.48) 1185.39 (1168.99 to 1202.02) 1 (0.99 to 1.02), 0.87
ECV (%) 27.2 (26.4 to 28.1) 26.4 (25.6 to 27.1) 1.0 (0.9 to 1.0), 0.06
n=81 with imputation for missing baseline or follow- up values.
AD, aortic distensibility; ECV, myocardial extracellular volume; LVEF, left ventricular ejection fraction; LVLS, left ventricular longitudinal strain; LV mass, left ventricular mass; 
PLVTw, peak left ventricular twist.
Table 4 Aortic distensibility (AD) between baseline and year 1
Comparison
AD (10−3 mm Hg−1)
Geometric mean (95% CI), 
(unadjusted)
Ratio (95% CI), P value
Unadjusted Adjusted 1 Adjusted 2
Combined TA1 and TA2 (n=81)
Baseline
1 year
3.0 (2.7 to 3.4) 3.6 (3.1 to 4.1) 1.2 (1.1 to 1.3), <0.01 na na
TA1 at 1 year
(all n=40)
TA2 at 1 year
(all n=41)
3.8 3.4 0.9 (0.7 to 1.2), 0.49 0.9 (0.7 to 1.2), 0.42 0.9 (0.8 to 1.2), 0.56
Combined TA1 and TA2 at 
1 year
(non- responders n=38)
Combined TA1 and TA2 at 
1 year (responders n=43)
3.5 3.6 1.0 (0.8 to 1.4), 0.87 1.0 (0.8 to 1.2), 0.79 1.0 (0.8 to 1.2), 0.86
TA1 at 1 year
(non- responders n=17)
TA1 at 1 year (responders 
n=23)
3.6 3.9 1.1 (0.7 to 1.6), 0.73 1.0 (0.7 to 1.3), 0.84 1.0 (0.7 to 1.3), 0.82
TA1 at 1 year
(responders n=23)
TA2a at 1 year (responders 
n=13)
3.9 2.8 0.7 (0.4 to 1.2), 0.19 0.8 (0.5 to 1.2), 0.29 0.9 (0.6 to 1.4), 0.56
Differences between groups, either unadjusted, adjusted for baseline AD or (additionally) adjusted for age, sex, systolic blood pressure and pack years smoking (±baseline 
Disease Activity Score with 28 joint count erythrocyte sedimentation rate (DAS28ESR) as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
Adjusted 1, adjusted for baseline AD; Adjusted 2, adjusted for baseline AD, age, sex, systolic BP and pack years smoking (± baseline DAS28ESR as applicable); non- responders, 
patients with DAS28≥2.6 at 48 weeks; responders, patients with DAS28 <2.6 at 48 weeks; TA1, immediate etanercept (ETN) and methotrexate (MTX) treatment; TA2, first- line 
MTX ± additional conventional synthetic disease- modifying antirheumatic drug; TA2a, TA2 patients that continued csDMARD and did not escalate to delayed ETN/MTX at week 
24.
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in treatment- naive ERA and change with randomised RA treat-
ments. This study capitalised on a real- life, ERA, DMARD and 
prior corticosteroid- naive RCT and interrogated multiple CV 
parameters. Patients had no history of CVD, no CV symptoms, 
were in NYHA Class 1 and those with diabetes mellitus and/or 
more than one CVD risk factor were excluded. All analyses were 
adjusted for age and gender, the principal drivers of vascular 
stiffness, and blood pressure and smoking where indicated.
The choice of AD as the primary endpoint in this study was 
based on its ability to predict major CV events independently 
of traditional clinical risk scoring models in patients without 
known CVD,17 25 its high reproducibility18 and previous use in 
a pilot study in RA.19 The predictive ability of AD is thus of 
particular advantage in this asymptomatic CVD population. The 
presence of abnormal vascular stiffness (adjusted for known risks 
including blood pressure) at the earliest stage of diagnosis of RA 
highlights the increased risk in this population.
Myocardial ECV is a measure of diffuse myocardial fibrosis 
and an indicator of adverse outcome in several forms of heart 
disease.26 Increased ECV has been reported in established RA.27 
Our observation that ECV is already increased on diagnosis of 
ERA suggests a period of latent myocardial involvement before 
clinical presentation of RA. We observed non- ischaemic areas of 
focal fibrosis (LGE) in just over 10% of patients, although all 
except two had non- specific RV insertion point fibrosis only. A 
previous report in established RA reported much more common 
focal fibrosis (46%),27 suggesting progression of this finding over 
time in RA. Our observation of reduced LV mass at baseline adds to 
literature consistent with21 22 and in contrast to ours.28 29 Further 
investigation including cardiometabolic changes30 is needed 
to clarify these apparent contradictions. Measures of LV func-
tion and strain however were not impaired compared with the 
control population. These indices likely reflect the consequences 
of abnormal pathophysiological processes, which are more likely 
to affect patients with long- standing RA.27 This and, similarly, 
the absence of visual perfusion defects would be less likely to be 
captured in our asymptomatic cohort.
RA treatment (without addition of prognostic cardiac pharma-
cotherapy) improved CV abnormalities within a year of protoco-
lised treatment, still evident at the end of year 2. AD improved 
(by 20% at year 1), which broadly translates to HRs of 1.12 
(composite events) and 1.13 (non- fatal cardiac events), that is, 
reductions of 12% and 13%, respectively.25 The measured effect 
on AD was not confounded by any increase in antihypertensive 
medication during the study. Of the secondary outcomes (not 
powered for) ECV showed the greatest potential for improve-
ment. Future larger, longitudinal studies in RA can confirm the 
basis for raised myocardial ECV, the prognostic implication and 
whether RA treatment improves ECV.
First- line ETN+MTX was not significantly superior to initial 
MTX- TT strategy in improving AD and there was no clear rela-
tionship between the improvement in vascular stiffness and RA 
response. Remission defined response status, aligned with the 
primary endpoint of the associated VEDERA RCT although 
holds potential weaknesses.12 However, we also did not identify 
an association with cumulative burden of disease activity, nor 
did change in AD correlate with change in ESR or CRP (data 
not shown). Previous studies to report on such associations have 
been contradictory.31 32 It is conceivable that an association may 
not be observed with arterial stiffening that is an integration of 
several processes of the structural and cellular elements of the 
vessel wall and not solely due to inflammation.
Collectively, these data speak to several study findings33 34 
indicating benefits of RA therapies not only include effect on 
systemic inflammation,35 but cardiometabolic profile36 and a 
targeted effect on key immune mediators of CVD. Similarly, 
a prospective cohort study suggested that after accounting for 
other risk factors and treatment response, subjects actively 
receiving bDMARDs experienced lower CV event risk, which 
was not observed in those who discontinued.37 The concept of 
targeted therapeutics in atherosclerosis is indirectly supported 
by seminal genetic and experimental studies and recent trials of 
blockade of IL-1 β  and MTX.
6
These data have wider implications on RA management strat-
egies including DMARD tapering. While this study was not 
designed to address this, by demonstrating improvement in 
CV markers, and until further data are available, this should be 
considered if contemplating drug tapering.
The principal limitation of our study is the use of surrogate 
markers for CV risk. However, early termination of a study 
Table 5 Aortic distensibility (AD) baseline and 2 years
Comparison
AD (10−3 mm Hg−1)
Geometric mean (95% CI) 
(unadjusted)
Ratio (95% CI), P value
Unadjusted Adjusted 1 Adjusted 2
Combined TA1 and TA2 (n=81)
Baseline
2 years
3.0 (2.7 to 3.4) 3.6 (3.1 to 4.1) 1.1 (1 to 1.4), 0.05 na na
TA1 at 2 years
(all n=40)
TA2 at 2 years
(all n=41)
3.7 3.4 0.9 (0.7 to 1.2), 0.59 0.9 (0.7 to 1.2), 0.6 0.9 (0.7 to 1.2), 0.65
Combined TA1 and TA2 at 2 
years
(non- responders n=38)
Combined TA1 and TA2 at 2 
years (responders n=43)
3.5 3.6 1.0 (0.8 to 1.4), 0.83 1.0 (0.8 to 1.4), 0.91 1.0 (0.7 to 1.4), 0.95
TA1 at 2 years
(non- responders n=17)
TA1 at 2 years (responders 
n=23)
3.5 3.8 1.1 (0.7 to 1.7), 0.75 1.1 (0.6 to 1.7), 0.83 1.1 (0.6 to 1.8), 0.83
TA1 at 2 years
(responders n=23)
TA2a at 2 years (responders 
n=13)
3.8 3.4 0.9 (0.6 to 1.4), 0.56 0.9 (0.6 to 1.5), 0.70 0.9 (0.5 to 1.6), 0.70
Differences between groups, either unadjusted, adjusted for baseline AD or (additionally) adjusted for age, sex, systolic blood pressure and pack years smoking (±baseline 
DAS28ESR as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
AD, aortic distensibility (10-3mm Hg-1); Adjusted 1, adjusted for baseline AD; DAS28- ESR, Disease Activity Score-28 erythrocyte sedimentation rate; non- responders, patients 
with DAS28 >/=2.6 at 48 weeks; responders, patients with DAS28 <2.6 at 48 weeks; TA1, immediate etanercept (ETN) and methotrexate (MTX) treatment; TA2, first- line MTX ± 
additional conventional synthetic disease- modifying antirheumatic drug (csDMARD); TA2a, TA2 patients that continued csDMARD and did not escalate to delayed ETN/MTX at 
week 24.
 o
n
 August 29, 2020 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217653 on 28 August 2020. Downloaded from
 
8 Plein S, et al. Ann Rheum Dis 2020;0:1–9. doi:10.1136/annrheumdis-2020-217653
Rheumatoid arthritis
that recruited over 3000 patients8 emphasises this reality in 
the investigation of CVD in RA. Also, a longer, observational 
evaluation would inform on the pathophysiological sequence 
of events in relation to RA disease course and future events. 
Our study was not designed to assess for the known deleterious 
effects of corticosteroid38 and non- steroidal anti- inflammatory 
drug (NSAID) comedication, however, equivalent corticosteroid 
usage across both treatment arms ensures balance in any possible 
interaction.12
In summary, this is a first RCT- derived longitudinal study in a 
new onset, treatment- naïve ERA cohort with no history of CVD. 
This study demonstrated the presence of CV abnormalities at 
the earliest stage of RA and the ability of RA therapy to improve 
vascular stiffness. This improvement was not however associated 
with response status and disease activity burden.
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